Tonix Pharmaceuticals Holding Corp. (TNXP)

2.54
0.16 5.93
NASDAQ : Health Technology
Prev Close 2.70
Open 2.57
Day Low/High 2.25 / 2.58
52 Wk Low/High 2.30 / 96.00
Volume 156.73K
Avg Volume 403.70K
Exchange NASDAQ
Shares Outstanding 1.57M
Market Cap 4.24M
EPS -9.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For Crystalline Tianeptine Oxalate Salt, The Active Ingredient Of TNX-601

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For Crystalline Tianeptine Oxalate Salt, The Active Ingredient Of TNX-601

NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Joins The Alliance For Biosecurity

Tonix Pharmaceuticals Joins The Alliance For Biosecurity

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces That The European Patent Office Opposition Division Has Upheld Its Patent For The Use Of The Active Ingredient In TNX-102 SL, Cyclobenzaprine, For The Treatment Of PTSD

Tonix Pharmaceuticals Announces That The European Patent Office Opposition Division Has Upheld Its Patent For The Use Of The Active Ingredient In TNX-102 SL, Cyclobenzaprine, For The Treatment Of PTSD

Patent Expected to Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of PTSD

Tonix Pharmaceuticals Announces Completion Of Long-Term Exposure Studies In Participants With PTSD To Evaluate The Tolerability Of TNX-102 SL 5.6 Mg

Tonix Pharmaceuticals Announces Completion Of Long-Term Exposure Studies In Participants With PTSD To Evaluate The Tolerability Of TNX-102 SL 5.6 Mg

Company Expects this Long-Term Safety Exposure Data to Satisfy Long-Term Exposure Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromyalgia

Tonix Pharmaceuticals Announces Publication Of Paper On Triple Reuptake Inhibitor TNX-1600 (formerly D-578) In The European Journal Of Pharmacology

Tonix Pharmaceuticals Announces Publication Of Paper On Triple Reuptake Inhibitor TNX-1600 (formerly D-578) In The European Journal Of Pharmacology

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals To Speak At The 2019 Annual National Association Of Veterans' Research And Education Foundations (NAVREF) Conference

Tonix Pharmaceuticals To Speak At The 2019 Annual National Association Of Veterans' Research And Education Foundations (NAVREF) Conference

NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting With FDA For TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) As A Clinical Candidate For Agitation In Alzheimer's Disease

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting With FDA For TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) As A Clinical Candidate For Agitation In Alzheimer's Disease

FDA Official Minutes Support Tonix's Plan to File an IND in First Quarter 2018 for a Phase 2 Study